Boehringer Ingelheim International GmbH;Zealand Pharma A/S
发明人:
Dieter Wolfgang Hamprecht,Jakob Lind Tolborg,Ditte Riber
申请号：
US13720041
公开号：
US20130316941A1
申请日:
2012.12.19
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
